J
Jayan Nagendran
Researcher at University of Alberta
Publications - 141
Citations - 3154
Jayan Nagendran is an academic researcher from University of Alberta. The author has contributed to research in topics: Medicine & Lung transplantation. The author has an hindex of 24, co-authored 108 publications receiving 2561 citations. Previous affiliations of Jayan Nagendran include University of Alberta Hospital & Alberta Health Services.
Papers
More filters
Journal ArticleDOI
Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility
Jayan Nagendran,Stephen L. Archer,Daniel Soliman,Vikram Gurtu,Rohit Moudgil,Alois Haromy,Chantal St. Aubin,Linda Webster,Ivan M. Rebeyka,David B. Ross,Peter E. Light,Jason R.B. Dyck,Evangelos D. Michelakis +12 more
TL;DR: The ability of PDE5 inhibitors to increase RV inotropy and to decrease RV afterload without significantly affecting systemic hemodynamics makes them ideal for the treatment of diseases affecting the RV, including pulmonary arterial hypertension.
Journal ArticleDOI
Genome-wide hypermutation in a subpopulation of stationary-phase cells underlies recombination-dependent adaptive mutation.
Joel Torkelson,Reuben S. Harris,Mary Jane Lombardo,Jayan Nagendran,Carl Thulin,Susan M. Rosenberg +5 more
TL;DR: It is reported that lac adaptive mutations are associated with hypermutation in unselected genes, in all replicons in the cell, and the adaptive mutagenesis mechanism is not directed to the lac genes in a Lamarckian manner, nor to the F′ replicon carrying lac.
Journal ArticleDOI
A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension.
Gopinath Sutendra,Peter Dromparis,Roxane Paulin,Sotirios Zervopoulos,Alois Haromy,Jayan Nagendran,Evangelos D. Michelakis +6 more
TL;DR: The transition from a compensated (cRVH) to a decompensated hypertrophied (dRVHC) right ventricular failure was studied in animal models as mentioned in this paper.
Journal ArticleDOI
Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients
Evangelos D. Michelakis,Vikram Gurtu,Linda Webster,Gareth Barnes,Geoffrey Watson,Luke Howard,John Cupitt,Ian Paterson,Richard B. Thompson,Kelvin Chow,Declan P. O'Regan,Lan Zhao,John Wharton,David G. Kiely,Adam Kinnaird,Aristeidis E. Boukouris,Christopher W. White,Jayan Nagendran,Darren H. Freed,Stephen J. Wort,J. Simon R. Gibbs,Martin R. Wilkins +21 more
TL;DR: This first-in-human trial of a mitochondria-targeting drug in iPAH demonstrates that PDK is a druggable target and offers hemodynamic improvement in genetically susceptible patients, paving the way for novel precision medicine approaches in this disease.
Journal ArticleDOI
Normothermic ex-vivo preservation with the portable Organ Care System Lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, non-inferiority, phase 3 study
Gregor Warnecke,Dirk Van Raemdonck,Michael A. Smith,Gilbert Massard,Jasleen Kukreja,Federico Rea,Gabriel Loor,Fabio De Robertis,Jayan Nagendran,Kumud Dhital,Francisco Javier Moradiellos Díez,Christoph Knosalla,Christian Bermudez,Steven Tsui,Kenneth R. McCurry,I. Wang,Tobias Deuse,Guy Lesèche,Pascal Thomas,Igor Tudorache,Christian Kühn,Murat Avsar,Bettina Wiegmann,Wiebke Sommer,Arne Neyrinck,Marco Schiavon,Fiorella Calabrese,Nichola Santelmo,Anne Olland,Pierre-Emanuel Falcoz,Andre R. Simon,Andrés Varela,Joren C. Madsen,Marshall I. Hertz,Axel Haverich,Abbas Ardehali +35 more
TL;DR: The INSPIRE trial met its primary effectiveness and safety endpoints and further research is needed to see whether the reduced incidence of PGD3 within 72 h of a transplant might translate into earlier recovery after improved long-term recovery in the non-inferiority patients.